[Form 4] VOLITIONRX LTD Insider Trading Activity
VolitionRx insider filing: Michel Gaetan, the company's Chief Operating Officer and a director, reported a transaction dated 09/28/2025 reducing his direct common stock holding. The Form 4 shows a Code F disposition of 11,362 shares at $0.605, leaving 369,079 shares beneficially owned directly after the reported transaction. The filing explains these 11,362 shares represent the portion of 22,725 restricted stock units retained by VolitionRx to satisfy tax withholding upon settlement; the form states no shares were sold by the reporting person or the company in the process. The form is signed by Gaetan on 09/30/2025.
VolitionRx insider filing: Michel Gaetan, Chief Operating Officer e consigliere della società, ha riportato una transazione del 28/09/2025 che riduce la sua partecipazione diretta di azioni ordinarie. Il Form 4 mostra una disposizione Code F di 11.362 azioni a 0,605$, lasciando 369.079 azioni detenute direttamente dall’interessato dopo l’operazione descritta. La dichiarazione indica che queste 11.362 azioni rientrano nella porzione di 22.725 unità azionarie vincolate trattenute da VolitionRx per soddisfare le ritenute fiscali al momento dello settlement; il modulo afferma che nessuna azione è stata venduta né dall’intervistato né dall’azienda nel corso dell’operazione. Il modulo è stato firmato da Gaetan il 30/09/2025.
VolitionRx insider filing: Michel Gaetan, Director Ejecutivo y Director de la compañía, reportó una transacción del 28/09/2025 que reduce su participación directa de acciones comunes. El Formulario 4 muestra una disposición Code F de 11.362 acciones a 0,605$, dejando 369.079 acciones en propiedad directa tras la operación reportada. El filing explica que estas 11.362 acciones representan la porción de 22.725 unidades de acciones restringidas retenidas por VolitionRx para satisfacer la retención de impuestos al momento de la liquidación; el formulario indica que no se vendieron acciones por la persona reportante ni por la empresa en el proceso. El formulario está firmado por Gaetan el 30/09/2025.
VolitionRx 내부 공시: 회사의 최고운영책임자이며 이사인 미셸 고탱은 2025년 9월 28일자 거래로 자신의 직접 보통주 지분을 감소시켰습니다. Form 4는 11,362주를 0.605달러에 처분한 Code F를 표시하며, 보고된 거래 직후 369,079주를 직접 보유하고 있습니다. 신청서는 이 11,362주가 매각이 아닌 세금 원천징수를 충족하기 위해 VolitionRx가 보유한 22,725주의 제한주(Restricted Stock Units)의 일부임을 설명합니다; 양식에는 보고자나 회사가 과정 중에 주식을 매도하지 않았다고 명시되어 있습니다. 양식은 2025년 9월 30일에 고탱이 서명했습니다.
VolitionRx insider filing: Michel Gaetan, directeur des opérations et administrateur de l’entreprise, a signalé une opération datée du 28/09/2025 réduisant sa participation directe d’actions ordinaires. Le Formulaire 4 indique une cession Code F de 11 362 actions à 0,605$, laissant 379 079 actions détenues directement après l’opération reportée. Le document précise que ces 11 362 actions représentent la portion de 22 725 unités d’actions restreintes conservées par VolitionRx pour satisfaire les retenues d’impôt à la liquidation; le formulaire indique qu’aucune action n’a été vendue ni par la personne déclarante ni par l’entreprise au cours de la transaction. Le formulaire est signé par Gaetan le 30/09/2025.
VolitionRx Insider Filing: Michel Gaetan, Chief Operating Officer und Direktor des Unternehmens, meldete eine Transaktion vom 28.09.2025, die seinen direkten Inhaberaktienanteil reduziert. Das Formular 4 zeigt eine Code-F-Verfügung von 11.362 Aktien zu 0,605 $, wodurch 369.079 Aktien direkt nach der gemeldeten Transaktion wirtschaftlich dem Meldenden gehören. Die Einreichung erläutert, dass diese 11.362 Aktien den Teil von 22.725 Restricted Stock Units darstellen, die von VolitionRx gehalten werden, um die Steuerabzüge bei der Abwicklung zu erfüllen; im Formular wird angegeben, dass keine Aktien verkauft wurden von der meldenden Person oder dem Unternehmen im Verlauf der Transaktion. Das Formular ist von Gaetan am 30.09.2025 unterschrieben.
تقرير داخل VolitionRx: ميشيل غايتان، المدير التنفيذي للعمليات ومدير الشركة، أبلغ عن صفقة بتاريخ 2025/09/28 تقلل من حصته المباشرة من الأسهم العادية. يُظهر النموذج 4 تصفية من النوع Code F لعدد 11,362 سهمًا بسعر 0.605 دولار، مع بقاء 369,079 سهمًا مملوكة بشكل مستهدف مباشرة بعد الصفقة المبلغ عنها. تشرح المستندة أن هذه الأسهم الـ11,362 تمثل جزءًا من 22,725 وحدة أسهم مقيدة احتُفظ بها من قبل VolitionRx لتلبية احتجاز الضرائب عند التسوية؛ يذكر النموذج أنه لم يتم بيع أي أسهم من قبل الشخص المبلغ عنه أو الشركة خلال العملية. تم توقيع النموذج من قبل غايتان في 30/09/2025.
VolitionRx 内部披露: 公司首席运营官兼董事 Michel Gaetan 报告了一笔日期为 2025/09/28 的交易，减少了他直接持有的普通股。Form 4 显示以 0.605 美元价格处置 11,362 股，交易后直接持有的受益股数为 369,079 股。披露文件解释这 11,362 股代表 VolitionRx 为满足结算时的税务代扣而保留的 22,725 股限制性股票单位（RSU）之一部分；表格声明在此过程中 未有股票被出售，无论是报告人还是公司。该表格由 Gaetan 于 2025/09/30 签署。
- None.
- None.
Insights
TL;DR: Routine tax-withholding share retention on RSU settlement; not a sale by the insider and likely minimal governance concern.
The filing documents a common practice where a company retains shares to cover employee tax obligations when restricted stock units vest. Because the reporting person did not sell shares and the company retained shares for withholding, this does not indicate an opportunistic insider sale. The transaction reduces the insider's direct share count by 11,362 shares and reflects settlement of 22,725 RSUs. For governance analysis, this is procedural and does not signal control changes or delegation issues.
TL;DR: The disclosure is an administrative share retention for tax withholding; impact on float and valuation is likely immaterial.
The Form 4 reports a Code F disposition at $0.605 per share for 11,362 shares, resulting from withholding on vested RSUs rather than an open-market sale. The insider's remaining direct stake is 369,079 shares. Absent additional context on total outstanding shares or larger insider activity, this single administrative action is unlikely to meaningfully affect supply, demand, or investor perception.
VolitionRx insider filing: Michel Gaetan, Chief Operating Officer e consigliere della società, ha riportato una transazione del 28/09/2025 che riduce la sua partecipazione diretta di azioni ordinarie. Il Form 4 mostra una disposizione Code F di 11.362 azioni a 0,605$, lasciando 369.079 azioni detenute direttamente dall’interessato dopo l’operazione descritta. La dichiarazione indica che queste 11.362 azioni rientrano nella porzione di 22.725 unità azionarie vincolate trattenute da VolitionRx per soddisfare le ritenute fiscali al momento dello settlement; il modulo afferma che nessuna azione è stata venduta né dall’intervistato né dall’azienda nel corso dell’operazione. Il modulo è stato firmato da Gaetan il 30/09/2025.
VolitionRx insider filing: Michel Gaetan, Director Ejecutivo y Director de la compañía, reportó una transacción del 28/09/2025 que reduce su participación directa de acciones comunes. El Formulario 4 muestra una disposición Code F de 11.362 acciones a 0,605$, dejando 369.079 acciones en propiedad directa tras la operación reportada. El filing explica que estas 11.362 acciones representan la porción de 22.725 unidades de acciones restringidas retenidas por VolitionRx para satisfacer la retención de impuestos al momento de la liquidación; el formulario indica que no se vendieron acciones por la persona reportante ni por la empresa en el proceso. El formulario está firmado por Gaetan el 30/09/2025.
VolitionRx 내부 공시: 회사의 최고운영책임자이며 이사인 미셸 고탱은 2025년 9월 28일자 거래로 자신의 직접 보통주 지분을 감소시켰습니다. Form 4는 11,362주를 0.605달러에 처분한 Code F를 표시하며, 보고된 거래 직후 369,079주를 직접 보유하고 있습니다. 신청서는 이 11,362주가 매각이 아닌 세금 원천징수를 충족하기 위해 VolitionRx가 보유한 22,725주의 제한주(Restricted Stock Units)의 일부임을 설명합니다; 양식에는 보고자나 회사가 과정 중에 주식을 매도하지 않았다고 명시되어 있습니다. 양식은 2025년 9월 30일에 고탱이 서명했습니다.
VolitionRx insider filing: Michel Gaetan, directeur des opérations et administrateur de l’entreprise, a signalé une opération datée du 28/09/2025 réduisant sa participation directe d’actions ordinaires. Le Formulaire 4 indique une cession Code F de 11 362 actions à 0,605$, laissant 379 079 actions détenues directement après l’opération reportée. Le document précise que ces 11 362 actions représentent la portion de 22 725 unités d’actions restreintes conservées par VolitionRx pour satisfaire les retenues d’impôt à la liquidation; le formulaire indique qu’aucune action n’a été vendue ni par la personne déclarante ni par l’entreprise au cours de la transaction. Le formulaire est signé par Gaetan le 30/09/2025.
VolitionRx Insider Filing: Michel Gaetan, Chief Operating Officer und Direktor des Unternehmens, meldete eine Transaktion vom 28.09.2025, die seinen direkten Inhaberaktienanteil reduziert. Das Formular 4 zeigt eine Code-F-Verfügung von 11.362 Aktien zu 0,605 $, wodurch 369.079 Aktien direkt nach der gemeldeten Transaktion wirtschaftlich dem Meldenden gehören. Die Einreichung erläutert, dass diese 11.362 Aktien den Teil von 22.725 Restricted Stock Units darstellen, die von VolitionRx gehalten werden, um die Steuerabzüge bei der Abwicklung zu erfüllen; im Formular wird angegeben, dass keine Aktien verkauft wurden von der meldenden Person oder dem Unternehmen im Verlauf der Transaktion. Das Formular ist von Gaetan am 30.09.2025 unterschrieben.
FAQ
What did Michel Gaetan disclose on the Form 4 for VNRX?
Why were 11,362 shares disposed according to the filing?
What is the reporting person’s role at VolitionRx (VNRX)?
When was the Form 4 signed and filed?
